Saturday 17 October 2026
Export BIAF’s income statement to Excel — free account
bioAffinity Technologies, Inc.
BIAF Healthcare Diagnostics & Research
In the quarter to June 2026, revenue grew 19.0%, EPS grew 87.5%, free cash flow fell 23.7% and total debt rose 569.7%, each against the same quarter a year earlier.
3.73
0.23
−5.81%
Follow BIAF
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | |
|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 4 | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Altman Z-Score |
(10.54) | (13.01) | (7.95) | (0.44) | — | — | — |
P/S ratio |
0.33 | 1.18 | 5.83 | 0.00 | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Altman Z″-Score (non-manufacturers) |
(22.01) | (35.80) | (21.31) | 3.99 | — | — | — |
Beneish M-Score |
(5.49) | (2.03) | 843.49 | — | — | — | — |
P/Operating CF |
(0.79) | (6.59) | (9.13) | (5.40) | — | — | — |
P/B ratio |
0.28 | 4.25 | 3.04 | 0.64 | — | — | — |
Price to Tangible BV |
0.39 | 26.18 | 5.64 | 0.64 | — | — | — |
EV/Sales |
(0.61) | 1.13 | 5.22 | 0.00 | — | — | — |
EV/EBITDA |
0.37 | 0.00 | 0.00 | 2.13 | — | — | — |
EV/Operating CF |
0.40 | (1.46) | (2.19) | 1.02 | — | — | — |
EV/FCF |
0.40 | (1.44) | (2.18) | 1.02 | — | — | — |
Quick Ratio |
2.41 | 0.72 | 1.62 | 10.03 | 0.10 | 0.01 | 0.12 |
Current Ratio |
2.60 | 0.87 | 1.77 | 10.50 | 0.11 | 0.01 | 0.13 |
Net Debt/EBITDA |
0.57 | 0.06 | 0.26 | 5.74 | (5.81) | (3.84) | (1.12) |
Debt/Assets |
6.20% | 9.77% | 10.16% | 2.07% | 781.97% | 6,872.73% | 608.83% |
Debt/Equity |
0.09 | 0.24 | 0.17 | 0.02 | (0.72) | (0.91) | (0.99) |
Asset Turnover |
0.71 | 1.27 | 0.25 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.63 | 0.80 | 0.76 | 0.50 | 0.32 | 0.30 | 0.75 |
Capex/Depreciation |
(0.12) | (0.13) | (0.09) | (0.11) | 0.00 | 0.00 | 0.00 |
Interest Coverage |
(238.12) | (96.79) | (214.91) | (1.58) | (2.20) | (13.59) | (28.42) |
| (301.83%) | (242.44%) | (99.84%) | 343.53% | 41.00% | 62.79% | 0.00% | |
| (170.65%) | (122.70%) | (77.80%) | (119.60%) | (791.34%) | (1,807.24%) | 0.00% | |
ROIC |
(438.42%) | (262.35%) | (173.68%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(302.76%) | 26,278.49% | (363.50%) | (73.88%) | 54.55% | 66.12% | 81.70% |
Average Days of Receivables |
32.10 | 44.41 | 116.99 | 798.44 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
33.90% | 19.04% | 68.10% | 31,754.17% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
160.88% | 106.21% | 268.14% | 51,687.50% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.19 | 0.33 | 0.27 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
10.90% | 10.57% | 29.57% | 5,179.17% | 0.00% | — | — |
Graham Net Nets |
1.91 | (0.11) | 0.04 | 1.54 | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Earnings Yield |
(1,334.92%) | (84.66%) | (53.28%) | (111.74%) | — | — | — |
Free Cash Flow Yield |
(462.09%) | (66.42%) | (41.08%) | (57.99%) | — | — | — |
Revenue per Share |
53.68 | 346.74 | 130.54 | 0.48 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(81.26) | (269.07) | (311.23) | (407.08) | (347.29) | (0.30) | (0.34) |
Capex per Share |
(0.53) | (2.93) | (1.18) | (22.00) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(81.79) | (272.00) | (312.41) | (429.08) | (347.29) | (0.30) | (0.34) |
Cash per Share |
56.18 | 40.94 | 145.44 | 1,141.38 | 230.61 | 0.01 | 0.08 |
Shareholders Equity per Share |
63.39 | 96.37 | 250.27 | 1,104.34 | (2,676.39) | (1.49) | (0.55) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
63.39 | 96.37 | 250.27 | 1,104.34 | (2,676.39) | (1.49) | (0.55) |
Free Cash Flow |
(9.39) | (7.34) | (6.06) | (4.29) | (2.05) | (2.21) | (2.49) |
Working Capital |
4.66 | (0.41) | 1.72 | 10.82 | (11.60) | (11.00) | (4.08) |
Capital Expenditures |
(0.06) | (0.08) | (0.02) | (0.22) | — | 0.00 | (0.01) |
Net Current Asset Value |
3.88 | (1.22) | 0.61 | 10.82 | (15.81) | (11.06) | (4.08) |
EV/EBIT |
0.35 | 0.00 | 0.00 | 1.03 | — | — | — |
Capex to Sales |
0.01 | 0.01 | 0.01 | 45.83 | — | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Other line items | |||||||
Depreciation/Fixed assets |
1.90 | 1.61 | 0.54 | 9.64 | 105.52 | 2.34 | 1.42 |
Cash ROIC |
(65.17%) | (169.07%) | (71.20%) | (18.89%) | 66.84% | 235.18% | (449.49%) |
Accounts Receivable Turnover |
7.33 | 9.60 | 6.16 | 0.80 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
4.83 | 7.52 | 3.67 | 0.00 | 0.02 | 0.15 | 0.00 |
Inventory Turnover |
104.24 | 259.59 | 145.08 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
65.79 | 60.23 | 126.80 | 251,850.00 | 17,520.00 | 3,146.89 | 936.50 |
Days of Inventory on Hand |
4.62 | 1.68 | 3.88 | 4,015.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
0.84 | 0.98 | 0.41 | 0.01 | 0.00 | 0.00 | — |
Average Payables |
0.87 | 0.80 | 0.47 | 0.29 | 0.21 | 0.15 | — |
Average Inventory |
0.04 | 0.02 | 0.01 | — | — | — | — |
Average Assets |
8.74 | 7.37 | 10.20 | 6.82 | 0.80 | 0.40 | — |
Average Common Equity |
4.94 | 3.73 | 7.95 | (2.37) | (15.43) | (11.58) | — |
Columns are period end dates · fundamentals updated 2 Oct 2026